Intellia Therapeutics Inc buy Wells Fargo & Company
Start price
10.01.25
/
50%
€10.22
Target price
10.01.26
€58.40
Performance (%)
-11.94%
End price
11.01.26
€9.00
Summary
This prediction ended on 11.01.26 with a price of €9.00. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.94%. Wells_Fargo___Compan has a follow-up prediction for Intellia Therapeutics Inc where he still thinks Intellia Therapeutics Inc is a Buy. Wells_Fargo___Compan has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | 0.423% | 0.423% | -5.024% |
| iShares Core DAX® | 3.153% | 1.504% | 9.129% |
| iShares Nasdaq 100 | 7.431% | -1.584% | 28.642% |
| iShares Nikkei 225® | 8.571% | -4.324% | 53.026% |
| iShares S&P 500 | 4.578% | 1.920% | 23.965% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Wells Fargo & Company from $70.00 to $60.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Wells_Fargo___Compan gewählte maximale Laufzeit wurde überschritten
Current prediction by Wells_Fargo___Compan for Intellia Therapeutics Inc
Stopped prediction by Wells_Fargo___Compan for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€9.50
28.02.25
28.02.25
€48.09
28.02.26
28.02.26
15.68%
01.03.26
01.03.26
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€13.35
18.11.24
18.11.24
€66.07
18.11.25
18.11.25
-46.02%
19.11.25
19.11.25